By Hilary Rosselot
Healx Presents During the 2022 Industry Updates Keynote at the 18th International Fragile X Conference
Wayne Chadwick, a Principal Pharmacologist at Healx Ltd., presented about the IMPACT-FXS trial during the Industry Updates keynote session at the 18th International Fragile X Conference.
IMPACT-FXS is a Phase 2 trial targeting multiple pathways associated with Fragile X to maximize the number of behaviors treated in individuals with Fragile X syndrome.
Wayne shared more about Healx, their novel AI approach to finding treatments, and their Phase 2 trial. Learn more about Healx and the IMPACT-FXS trial by watching their 2022 Industry Updates presentation or vising their MyFXResearch post.
Survey: Communication with Children Unaffected by Fragile X
University of Maryland [mpc_button preset="preset_191" url="url:https%3A%2F%2Fwww.surveymonkey.com%2Fr%2F8F8GFL6|title:Link||" font_preset="mpc_preset_62" font_color="#ffffff" font_size="12" font_line_height="1" font_transform="uppercase" font_align="inherit" title="Take the Survey" icon="fa fa-angle-right" icon_color="#ffffff" icon_size="12" icon_effect="stay-right" icon_gap="20" background_color="#00934a" border_css="border-width:2px;border-color:#00934a;border-style:solid;border-radius:5px;" padding_divider="true" padding_css="padding-top:11px;padding-right:30px;padding-bottom:11px;padding-left:40px;" margin_divider="true" margin_css="margin-top:6px;margin-right:10px;margin-bottom:4px;margin-left:10px;" hover_font_color="#ffffff" hover_icon_color="#ffffff" hover_background_color="#00934a" hover_border_css="border-width:2px;border-color:#00934a;border-style:solid;border-radius:5px;"] Hello, [...]
Clinical Trial: AFQ056 for Language Learning in Children with Fragile X Syndrome (NN107)
NN107 FX-LEARN is currently looking to enroll children with Fragile X Syndrome (FXS) for a research study conducted by the Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT). Dr. Elizabeth Berry-Kravis at Rush University is [...]